ILD Seen in Some Taking ADC for Brain Cancer Metastases

by | Feb 5, 2026 | Health

Spread the love
A systematic review and meta-analysis evaluate treatment-emergent adverse events associated with trastuzumab deruxtecan in patients with breast cancer brain metastases.
Medscape Medical News

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments